Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3302 |
Name | chordoma |
Definition | A notochordal cancer that derives_from cellular remnants of the notochord. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer notochordal cancer chordoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CDKN2A loss | Palbociclib | chordoma | sensitive | detail... |
CDKN2A loss | Abemaciclib | chordoma | sensitive | detail... |
MLH1 negative | Pembrolizumab | chordoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | chordoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01407198 | Phase I | Nilotinib | Nilotinib With Radiation for High Risk Chordoma | Active, not recruiting | USA | 0 |
NCT02383498 | Phase II | GI-6301 | The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma | Completed | USA | 0 |
NCT02389244 | Phase II | Regorafenib | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) | Active, not recruiting | FRA | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02989636 | Phase I | Nivolumab | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | Active, not recruiting | USA | 0 |
NCT03083678 | Phase II | Afatinib | Afatinib in Locally Advanced and Metastatic Chordoma | Completed | NLD | ITA | GBR | 0 |
NCT03110744 | Phase II | Palbociclib | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) | Completed | DEU | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Active, not recruiting | USA | 0 |
NCT03623854 | Phase II | Nivolumab + Relatlimab | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Completed | USA | 0 |
NCT03647423 | Phase Ib/II | Aldoxorubicin + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | Withdrawn | USA | 0 |
NCT03886311 | Phase II | Nivolumab + Talimogene laherparepvec + Trabectedin | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) | Recruiting | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | Completed | USA | 0 |
NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04718675 | Phase Ib/II | KB-0742 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | Terminated | USA | GBR | ESP | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04965753 | Phase I | FHD-609 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Terminated | USA | ITA | FRA | ESP | 0 |
NCT05041127 | Phase II | Cetuximab | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | Recruiting | USA | 0 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT05407441 | Phase Ib/II | Ipilimumab + Nivolumab + Tazemetostat | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Recruiting | USA | 0 |
NCT06794645 | Phase II | Pembrolizumab Pembrolizumab + Pemetrexed Disodium | Pembrolizumab and Pemetrexed for Progressive Chordoma | Recruiting | USA | 0 |